Intech Investment Management LLC Acquires Shares of 28,228 Vaxcyte, Inc. (NASDAQ:PCVX)

Intech Investment Management LLC acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 28,228 shares of the company’s stock, valued at approximately $3,226,000.

Several other institutional investors have also modified their holdings of PCVX. Riverview Trust Co acquired a new stake in Vaxcyte in the third quarter valued at $27,000. Blue Trust Inc. increased its holdings in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of Vaxcyte during the 2nd quarter worth about $35,000. J.Safra Asset Management Corp lifted its stake in Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after purchasing an additional 526 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its holdings in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. This trade represents a 8.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $109.27, for a total transaction of $546,350.00. Following the completion of the transaction, the senior vice president now directly owns 28,623 shares in the company, valued at $3,127,635.21. This represents a 14.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 102,464 shares of company stock valued at $11,455,576. Company insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PCVX. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Bank of America lifted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. BTIG Research upped their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC reiterated a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Mizuho upped their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $88.54 on Friday. The firm’s fifty day moving average is $107.89 and its two-hundred day moving average is $89.41. Vaxcyte, Inc. has a one year low of $48.24 and a one year high of $121.06. The firm has a market cap of $11.04 billion, a PE ratio of -19.25 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the firm posted ($0.91) earnings per share. Research analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.